NZ751394B2 - Compositions that assist skin healing and/or maintain skin health - Google Patents
Compositions that assist skin healing and/or maintain skin health Download PDFInfo
- Publication number
- NZ751394B2 NZ751394B2 NZ751394A NZ75139414A NZ751394B2 NZ 751394 B2 NZ751394 B2 NZ 751394B2 NZ 751394 A NZ751394 A NZ 751394A NZ 75139414 A NZ75139414 A NZ 75139414A NZ 751394 B2 NZ751394 B2 NZ 751394B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- tarranl
- annotation
- composition
- use according
- skin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 116
- 210000003491 Skin Anatomy 0.000 title claims abstract description 58
- 230000036559 skin health Effects 0.000 title claims abstract description 7
- 230000035876 healing Effects 0.000 title abstract description 9
- 206010015150 Erythema Diseases 0.000 claims abstract description 46
- 231100000321 erythema Toxicity 0.000 claims abstract description 45
- 102000008186 Collagen Human genes 0.000 claims abstract description 42
- 108010035532 Collagen Proteins 0.000 claims abstract description 42
- 229920001436 collagen Polymers 0.000 claims abstract description 42
- 229960005188 collagen Drugs 0.000 claims abstract description 42
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims abstract description 31
- 235000021317 phosphate Nutrition 0.000 claims abstract description 30
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims abstract description 23
- 230000001965 increased Effects 0.000 claims abstract description 12
- 235000013343 vitamin Nutrition 0.000 claims abstract description 11
- 239000011782 vitamin Substances 0.000 claims abstract description 11
- 229930003231 vitamins Natural products 0.000 claims abstract description 11
- 239000000284 extract Substances 0.000 claims description 27
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 235000007319 Avena orientalis Nutrition 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- -1 ents Substances 0.000 claims description 13
- 230000000699 topical Effects 0.000 claims description 12
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 11
- 229960004873 LEVOMENTHOL Drugs 0.000 claims description 11
- 229940041616 Menthol Drugs 0.000 claims description 11
- 239000003995 emulsifying agent Substances 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 229960003966 nicotinamide Drugs 0.000 claims description 11
- 235000005152 nicotinamide Nutrition 0.000 claims description 11
- 239000011570 nicotinamide Substances 0.000 claims description 11
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 239000003974 emollient agent Substances 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 230000002335 preservative Effects 0.000 claims description 7
- 239000003755 preservative agent Substances 0.000 claims description 7
- 239000003906 humectant Substances 0.000 claims description 6
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 6
- 229940101267 Panthenol Drugs 0.000 claims description 5
- 229940088594 Vitamin Drugs 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 5
- POYIQRAKQJCAJV-TXSQEWSBSA-L disodium;3-[2-carboxylatoethyl(dodecyl)amino]propanoate;[(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] dihydrogen phosphate Chemical compound [Na+].[Na+].CCCCCCCCCCCCN(CCC([O-])=O)CCC([O-])=O.OP(=O)(O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C POYIQRAKQJCAJV-TXSQEWSBSA-L 0.000 claims description 5
- 239000011619 pantothenol Substances 0.000 claims description 5
- 235000020957 pantothenol Nutrition 0.000 claims description 5
- 239000002562 thickening agent Substances 0.000 claims description 5
- 102000012422 Collagen Type I Human genes 0.000 claims description 4
- 108010022452 Collagen Type I Proteins 0.000 claims description 4
- 239000011703 D-panthenol Substances 0.000 claims description 4
- 235000004866 D-panthenol Nutrition 0.000 claims description 3
- 229960003949 Dexpanthenol Drugs 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 229940073669 ceteareth 20 Drugs 0.000 claims description 3
- 229940081733 cetearyl alcohol Drugs 0.000 claims description 3
- 210000002950 fibroblast Anatomy 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 241001465185 Drechslera avenae Species 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 claims description 2
- 229940068977 Polysorbate 20 Drugs 0.000 claims description 2
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical class CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 claims description 2
- 239000004067 bulking agent Substances 0.000 claims description 2
- 238000004040 coloring Methods 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000008387 emulsifying waxe Substances 0.000 claims description 2
- 150000002191 fatty alcohols Chemical class 0.000 claims description 2
- 239000003607 modifier Substances 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 241000209763 Avena sativa Species 0.000 claims 3
- BLMPQMFVWMYDKT-NZTKNTHTSA-N Carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 claims 1
- 241000257303 Hymenoptera Species 0.000 claims 1
- 229940035295 Ting Drugs 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000002085 irritant Substances 0.000 abstract description 7
- 229940029983 VITAMINS Drugs 0.000 abstract description 6
- 229940021016 Vitamin IV solution additives Drugs 0.000 abstract description 6
- 230000018109 developmental process Effects 0.000 abstract description 5
- 210000004027 cells Anatomy 0.000 description 23
- 244000075850 Avena orientalis Species 0.000 description 15
- 241001303601 Rosacea Species 0.000 description 12
- 201000004700 rosacea Diseases 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 230000002265 prevention Effects 0.000 description 9
- 108090001123 antibodies Proteins 0.000 description 7
- 102000004965 antibodies Human genes 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 210000002966 Serum Anatomy 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- 231100000486 side effect Toxicity 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 5
- 239000002609 media Substances 0.000 description 5
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 230000003712 anti-aging Effects 0.000 description 4
- 230000000111 anti-oxidant Effects 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 230000000475 sunscreen Effects 0.000 description 4
- 239000000516 sunscreening agent Substances 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 description 3
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 3
- 241000208680 Hamamelis mollis Species 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- 229940118846 Witch Hazel Drugs 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000003078 antioxidant Effects 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 239000008406 cosmetic ingredient Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229960003471 retinol Drugs 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 239000004408 titanium dioxide Substances 0.000 description 3
- 229960005196 titanium dioxide Drugs 0.000 description 3
- 235000010215 titanium dioxide Nutrition 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 244000144927 Aloe barbadensis Species 0.000 description 2
- 235000002961 Aloe barbadensis Nutrition 0.000 description 2
- 229940061720 Alpha Hydroxy Acids Drugs 0.000 description 2
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 2
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 2
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 2
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 229950009789 Cetomacrogol 1000 Drugs 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 2
- 229960005280 Isotretinoin Drugs 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- WYWIFABBXFUGLM-UHFFFAOYSA-N Oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 2
- 210000004927 Skin cells Anatomy 0.000 description 2
- 229940083542 Sodium Drugs 0.000 description 2
- XOLBLPGZBRYERU-UHFFFAOYSA-N Tin dioxide Chemical compound O=[Sn]=O XOLBLPGZBRYERU-UHFFFAOYSA-N 0.000 description 2
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 2
- 229960001727 Tretinoin Drugs 0.000 description 2
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 2
- 229940045997 Vitamin A Drugs 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 229940046009 Vitamin E Drugs 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- NCYCYZXNIZJOKI-OVSJKPMPSA-N all-trans-retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 2
- 235000011399 aloe vera Nutrition 0.000 description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000843 anti-fungal Effects 0.000 description 2
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 2
- 230000003115 biocidal Effects 0.000 description 2
- 229960003679 brimonidine Drugs 0.000 description 2
- 230000037319 collagen production Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 229940079866 intestinal antibiotics Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 2
- 229960001528 oxymetazoline Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 108091008117 polyclonal antibodies Proteins 0.000 description 2
- 230000001737 promoting Effects 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 201000004681 psoriasis Diseases 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 235000020945 retinal Nutrition 0.000 description 2
- 239000011604 retinal Substances 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- CRPCXAMJWCDHFM-DFWYDOINSA-M sodium;(2S)-5-oxopyrrolidine-2-carboxylate Chemical compound [Na+].[O-]C(=O)[C@@H]1CCC(=O)N1 CRPCXAMJWCDHFM-DFWYDOINSA-M 0.000 description 2
- 229910001887 tin oxide Inorganic materials 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 229930003799 tocopherols Natural products 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N trans-Retinyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 150000003712 vitamin E derivatives Chemical class 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 description 1
- KMOOCZWLFBSQCW-WZVSWZHRSA-N 2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2R,3R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(2-hydroxyethyl)-3-(methylaminomethyl)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine;(2S,5R,6R)-3,3-dimethy Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1.CNC[C@H]1[C@H](O)[C@@H](O)[C@H](CCO)O[C@H]1O[C@@H]1C(C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O KMOOCZWLFBSQCW-WZVSWZHRSA-N 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N 2-[6-[[amino-[[amino-(4-chloroanilino)methylidene]amino]methylidene]amino]hexyl]-1-[amino-(4-chloroanilino)methylidene]guanidine;hydron;dichloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- DWYHDSLIWMUSOO-UHFFFAOYSA-N 2-phenyl-1H-benzimidazole Chemical compound C1=CC=CC=C1C1=NC2=CC=CC=C2N1 DWYHDSLIWMUSOO-UHFFFAOYSA-N 0.000 description 1
- YZEUHQHUFTYLPH-UHFFFAOYSA-N AZOMYCIN Chemical compound [O-][N+](=O)C1=NC=CN1 YZEUHQHUFTYLPH-UHFFFAOYSA-N 0.000 description 1
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 1
- 235000005781 Avena Nutrition 0.000 description 1
- BDJRBEYXGGNYIS-UHFFFAOYSA-N Azelaic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N Berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 Berberine Drugs 0.000 description 1
- 210000004204 Blood Vessels Anatomy 0.000 description 1
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 1
- JBPWUHOUXBXCPN-UHFFFAOYSA-N C1(=CC=CC=C1)C=1NC=CN1.[Na].[Na] Chemical compound C1(=CC=CC=C1)C=1NC=CN1.[Na].[Na] JBPWUHOUXBXCPN-UHFFFAOYSA-N 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N Cetyl alcohol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 210000003467 Cheek Anatomy 0.000 description 1
- 229960004504 Chlorhexidine Hydrochloride Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N Coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- GZCGUPFRVQAUEE-KCDKBNATSA-N D-(+)-Galactose Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 210000004207 Dermis Anatomy 0.000 description 1
- 229960003722 Doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N Doxycycline Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 208000005679 Eczema Diseases 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N Ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 210000003953 Foreskin Anatomy 0.000 description 1
- 229940087559 GRAPE SEED Drugs 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000229754 Iva xanthiifolia Species 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 229940078795 Lactoferrin Drugs 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 241000539716 Mea Species 0.000 description 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N Mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 241001182492 Nes Species 0.000 description 1
- 210000001331 Nose Anatomy 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl methoxycinnamate Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N Oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- 229940049954 Penicillin Drugs 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- XCRBXWCUXJNEFX-UHFFFAOYSA-N Peroxybenzoic acid Chemical compound OOC(=O)C1=CC=CC=C1 XCRBXWCUXJNEFX-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N Phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 229960005323 Phenoxyethanol Drugs 0.000 description 1
- 229940113116 Polyethylene Glycol 1000 Drugs 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001451 Polypropylene glycol Polymers 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 229940091252 Sodium supplements Drugs 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229960001295 Tocopherol Drugs 0.000 description 1
- 229940068778 Tocotrienols Drugs 0.000 description 1
- 229940100611 Topical Cream Drugs 0.000 description 1
- 241000159243 Toxicodendron radicans Species 0.000 description 1
- 229940035936 Ubiquinone Drugs 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000000996 additive Effects 0.000 description 1
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 1
- 229940087168 alpha Tocopherol Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 229940121375 antifungals Drugs 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 229960000626 benzylpenicillin Drugs 0.000 description 1
- 229930015400 berberine Natural products 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- DDJSWKLBKSLAAZ-UHFFFAOYSA-N cyclotetrasiloxane Chemical compound O1[SiH2]O[SiH2]O[SiH2]O[SiH2]1 DDJSWKLBKSLAAZ-UHFFFAOYSA-N 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 201000004624 dermatitis Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 231100001003 eczema Toxicity 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000001605 fetal Effects 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 229930003944 flavones Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 229930003935 flavonoids Natural products 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- CYWFCPPBTWOZSF-UHFFFAOYSA-N ibufenac Chemical compound CC(C)CC1=CC=C(CC(O)=O)C=C1 CYWFCPPBTWOZSF-UHFFFAOYSA-N 0.000 description 1
- 229950009183 ibufenac Drugs 0.000 description 1
- 230000001976 improved Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 150000003816 isoflavonoids Chemical class 0.000 description 1
- 229930013032 isoflavonoids Natural products 0.000 description 1
- 235000012891 isoflavonoids Nutrition 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- CJCPHVRHJKYIJC-UHFFFAOYSA-N methyl 2-hydroxybenzoate;sodium Chemical compound [Na].COC(=O)C1=CC=CC=C1O CJCPHVRHJKYIJC-UHFFFAOYSA-N 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical class CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 230000000116 mitigating Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 229960002744 mometasone furoate Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 229940006093 opthalmologic coloring agents Diagnostic Drugs 0.000 description 1
- 229960001173 oxybenzone Drugs 0.000 description 1
- 230000002085 persistent Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000002165 photosensitisation Effects 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000020741 pine bark extract Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000002207 retinal Effects 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 125000000946 retinyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C1=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C1(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 239000004017 serum-free culture media Substances 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-N sodium;2-hydroxybenzoic acid Chemical compound [Na+].OC(=O)C1=CC=CC=C1O ABBQHOQBGMUPJH-UHFFFAOYSA-N 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000003390 teratogenic Effects 0.000 description 1
- 231100000378 teratogenic Toxicity 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 150000003611 tocopherol derivatives Chemical class 0.000 description 1
- 125000002640 tocopherol group Chemical group 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 125000003036 tocotrienol group Chemical group 0.000 description 1
- 229930003802 tocotrienols Natural products 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 229950004578 vitamin A palmitate Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- DLRVVLDZNNYCBX-ZZFZYMBESA-N β-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 description 1
Abstract
The present invention relates to compositions that assist skin healing and/or maintain skin health. The invention also relates to methods for increasing collagen in the skin and methods for treating or preventing the development or recurrence of erythema. The compositions according to the present invention comprise disodium lauriminodipropionate tocopheryl phosphates and, preferably, one or more anti-irritants and one or more vitamins. vention comprise disodium lauriminodipropionate tocopheryl phosphates and, preferably, one or more anti-irritants and one or more vitamins.
Description
itions that assist skin healing and/or maintain skin health
This application is a divisional of NZ 721641, all of which is hereby incorporated by
reference in its entirety.
Field of the invention
The present invention relates to compositions that assist skin healing and/or maintain
skin health, such as increasing collagen in the skin and/or treatment or prevention of the
development or recurrence of erythema. In on, the present invention relates to a
method for assisting skin healing and/or maintaining skin health.
Background of the invention
There are many causes of damage to the skin and many of these results in erythema.
Erythema is a skin condition characterised by abnormal redness of the skin. It is a
medical condition that is more significant than the normal flushed cheeks and/or nose in
the fair and sensitive skinned.
Erythema can occur in various skin conditions such as , psoriasis and rosacea.
It is a condition associated with inflammation of the skin and can be caused by external
irritation of the skin, for example, by over exposure to the sun or contact with irritating
substances such as plants (eg poison ivy), various als and some metals (eg
nickel in jewellery). Erythema can also occur when the skin is damaged by piercing with
an object or following an insect bite. This damage can be unintentional or an ed
part of a procedure such as skin needling. Erythema may also occur following various
medical and cosmetic procedures including laser ent, intense pulsed light (IPL)
treatment and microdermabrasion. ma may occur in response to an ic
reaction or an infection. It is a common side effect of radiotherapy treatment and can be
a side effect of tion or an illness. As a final example, erythema may occur as a
side effect of certain types of ing including vitamin A toxicity. Despite the
numerous known causes of erythema, in a significant proportion of cases the cause of
erythema is unknown.
Traditional treatments e otics such as doxycycline. Alternative oral
treatments include vitamin A medications, such as isotretinoin, steroids and antifungal
medications. These treatments have significant side effects, for example isotretinoin has
[Annotation] tarranl
None set by tarranl
[Annotation] tarranl
MigrationNone set by tarranl
[Annotation] tarranl
Unmarked set by l
[Annotation] l
None set by tarranl
[Annotation] tarranl
MigrationNone set by tarranl
[Annotation] tarranl
Unmarked set by tarranl
teratogenic side-effects. Antibiotics, antifungals and steroids can be administered
atopically but have limited efficacy and/or restrictions on use due to safety ns.
Other topical treatments include metronidazoie, azelaic acid, retinoic acid/retinaldehyde,
and vitamin C.
There are also light therapies to treat erythema, particUlarIy erythema ated with
rosacea and laser treatments involving the ablation of blood vessels.
1% hydrocortisone as a topical cream is one of the common short-term topical
treatments for erythema. '
Therevare limitations to all ofrthe’current treatments either with y or toxicity.
ma, particularly erythema associated with rosacea, can be a persistent and
chronic condition involving repeated remission and exacerbation. Many of the
treatments such as steroids or antibiotics are not appropriate for long term use. There is
a need for a non-prescription, non-steroid product that effectively assists the skin to heal
and, in particular, treats erythema. The minimisation of side-effects is particularly
important because some conditions ated with ma, such as rosacea, often
require lifelong symptomatic treatment. In addition. the subject’s skin may be so
sensitive that many l products are irritating. If a treatment is not sufficiently mild, it
can exacerbate rather than improve the symptoms. A better ent in these cases is
one that is effective, mild and can be used long term.
W0 2002/74290 describes treatment of rosacea with a non-steroidal anti-inflammatory
drug such as am, aspirin, ibufenac or naproxen in combination with nitroimidazole.
ses compositions for treating rosacea containing chitosan, a
chitosan derivative or a physiologically acceptable salt thereof and a short-medium
chain oxylic acid amide.
.25- Brimonidine was reported asouseful in the l treatment of erythema in WC
of oxymetazoline for
‘ treatin2011/fi77, disclosed cream itionsmptoms of rosacea including erythema, and disclosed the,
l treatment of rosacea with a combination of brimonidine and oxymetazoline.
[Annotation] tarranl
None set by tarranl
[Annotation] tarranl
MigrationNone set by tarranl
[Annotation] tarranl
Unmarked set by tarranl
[Annotation] tarranl
None set by tarranl
[Annotation] tarranl
MigrationNone set by tarranl
[Annotation] tarranl
Unmarked set by tarranl
sed the topical treatment of rosacea with berberine or'a
biologically equivalent'analogue thereof. WO 2012/001053 disclosed treatment of
rosacea with metronidazole esters.
' The ty of the dermis of the skin is collagen. The collagen both supports the skin
structure and retains moisture. Collagen fibres in the skin are reduced by exposure to
ultraviolet radiation. a dry environment andloxidation. The amount of collagen in the skin
also reduces with age. Reduction of collagen is associated with reduced ence and
”elasticity in the skin. Increased collagen production improves skin healing in patients
with erythema.‘ In addition, maintenance and/or increases in collagen levels in the skin
assist to maintain skin function and appearance. Overtime, this may prevent aging or
have an ing effect.
Retinoids are known to increase collagen production. r, they' have high
photoreactivity and require protection from light for stable storage. Retinoids also have
- significant incidence of e ons including photosensitisation of the skin, which
makes skin more susceptible to sunburn.
discloses the use of TGF-B and/or TGF—B degradation products in the
induction of collagen in the skin. WO 2011/040363 discloses a composition 'for
promoting en production comprising one or more. of D-aspartic acid, D-alanine
and tives and/or salts thereof. describes a compoSition for
promoting collagen productioncomprising one or more purine nucleic acid-related
substances.
Reference to any prior art in the specification is not, and should not be taken as, an
acknowledgment or any form of tion that this prior art forms part of the common
general knowledge in Australia or any Other jurisdiction or that this prior art could
‘25 reasonably be expected to be ascertained, understood and regarded as relevant by a
person skilled in the art.
[Annotation] tarranl
None set by tarranl
[Annotation] tarranl
MigrationNone set by tarranl
ation] tarranl
Unmarked set by tarranl
[Annotation] tarranl
None set by tarranl
[Annotation] tarranl
MigrationNone set by tarranl
[Annotation] tarranl
Unmarked set by tarranl
Summary of the invention
"The inventors of the present ion developed topical formulations intended as
soothing ts for sensitive skin types, that is, to soothe sensitive but undamaged
skin. The ations are intended to desensitise the skin by hydration and
moisturisation. Surprisingly, the ors ered that the formulations of the
invention have an additional and unexpected effect on healing damaged and inflamed
Skin with erythema. In addition, the formulations of the invention have been found to
increase the amount of en in the skin, which further s with skin healing. In
addition, the increase in collagen may protect the skin from degradation due to aging
' and/or provide an anti-ageing benefit.
in one aspect, the t invention provides a method of sing collagen in the
skin‘of a subject comprising topical administration of a physiologically effective amount
of a composition comprising disodium lauriminodipropionate tocopheryl phosphates. in
an alternate aspect, the present invention provides a method of increasing collagen in
the skin of a t comprising topical administration of a physiologically effective
amount of a composition comprising hamemalis virginiana water. In a preferred
embodiment, the subject is identified as likely to benefit from increased collagen in the
skin. The benefit from the increased collagen may be improved healing following skin
, the prevention or reduction of skin damage from exposure to ultraviolet
radiation or during therapeutic or cosmetic procedures such as laser treatment,
prevention of aging, maintenance of skin health, or ing. The increased production
of collagen may occur in any skin cell type. It is‘particularly beneficial for'the increase in
collagen to occur in fibroblasts. Where the increased production of collagen occurs in
lasts it may also occur in other skin cell types.
A physiologically effective amount of disodium laurimin’Odipropionate eryl
phosphates may be provided in the form of a topical formulation comprising 0.4 to 2%
wlw disodium lauriminodipropionate eryl phosphates.
In a preferred embodiment, administration of the ition increases production of
Collagal by about 10% or more, for example, when measured by fluorescent antibody
binding. In a» preferred embodiment, administration of the composition increases
[Annotation] tarranl
None set by tarranl
ation] tarranl
MigrationNone set by tarranl
[Annotation] tarranl
Unmarked set by tarranl
[Annotation] tarranl
None set by tarranl
[Annotation] tarranl
MigrationNone set by tarranl
[Annotation] tarranl
Unmarked set by tarranl
collagen III by about 20% or more and in a most preferred embodiment, administration
of the composition increases collagen III by about 40%.
Further, in a preferred embodiment, administration of the composition increases
production of collagen l by about 5% or more, for example, when measured by
florescent antibody binding. In a particularly preferred embodiment, administration of the
composition increases collagen l by about 15%. atively, the composition
administered to the subject is a composition that if administered to human foreskin
fibroblasts results in about a 40% increase in collagen Ill and/or about a 15% increase
in collagen | after)r about 60 hours of incubation with the composition.
'10 "In all alternative ments of the ion the subject can be a human subject.
In a second aspect, the present invention provides a method of treatment, prevention
or prevention of recurrence of erythema comprising topical administration of a
physiologically effective amount of a
. composition comprising disodium
lauriminodipropionate tocopheryl phosphates. in a preferred aspect, the method is a
.method of ent. In one embodiment, the t is identified as having erythema.
In an alternate embodiment, the subjectis fied as being at risk of developing
erythema. In another alternate embodiment, the subject is identified as being at risk of
recurrence of erythema. The erythema may be caused by any of the known causes
sed above. The cause of the erythema may be unknown. In one embodiment, the
'20 treatment of the erythema is post laser skin ents, chemical peels,
microdemiabrasion or skin needling. In another ment, the erythema treated is
» assoCiated with rosacea, psoriasis or eczema. In another embodiment, the method is to
prevent recurrence of rosacea. \
in a preferred embodiment, the administration of the composition reduced the Standard»
\25 Scalar Rating for the erythema by 75% or more by 7 days after use. It is preferred if the
Standard Scalar Rating is d by 80% or more by 7 days after use. In an ative
red embodiment, the stration of the composition reduced the Standard
Scalar fling for the erythema by 3.0 or more by 7 days after use. It is preferred if the
[Annotation] tarranl
None set by tarranl
[Annotation] tarranl
MigrationNone set by tarranl
[Annotation] tarranl
Unmarked set by tarranl
[Annotation] tarranl
None set by tarranl
[Annotation] l
MigrationNone set by tarranl
ation] tarranl
Unmarked set by tarranl
Standard Scalar Rating is reduced by 3.3 or more by 7 days after use. The Standard
Scalar Rating is explained below.
In an ative preferred embodiment, the administration of the composition resulted in
a magenta to blue shift, ie a* as measured by a Minolta Spectrometer Model CM-2600,
of -2.5 or a greater negative by 48 hours after use. it is preferred if the magenta to blue
shift is -2.8 or a greater negative by 48 hours after use. In an alternative preferred
embodiment, the magenta to blue shift is -4 or a greater negative by7 days after use. 'It
is preferred if the magenta to blue shift is -4.6 or a greater ve by 7 days after use.
In an alternative red embodiment, the administration of the ition results in
a AE. ie (AE) = «1(AL2 + Aa2 + Abz) as measured by a Minolta ometer, of 3.5 or
more by 48 hours after use. It is preferred if the AE is 3.7 or more by 48 hours after use.
In an alternative red embodiment, the AE is 5 or more by 7 days after use. It is
preferred if the AE~ is 5.7 or more by 7 days after use.
in a preferred embodiment, the composition of the present invention comprises
'15 disodium Iauriminodipropionate tooopheryl phosphates, at least one vitamin andrat least
one anti-irritant. The anti-irritant can be an emollient, a vitamin, an antioxidant or a
herbal extract. Vitamin E, liquid paraffin, aloe vera and avena sativa kernel extract are
suitable. Avena sativa kernel extract is preferred. The at least one n is preferably
nicotinamide. in a particularly red embodiment, the composition includes the two
.20 vitamins nicotinamide and panthenol. -
In. a particularly preferred ment, the composition of the present invention
comprises disodium lauriminodipropionate tooopheryl phosphates, at least one vitamin,
at least one anti-irritant and hamemalis iana water.
In one embodiment, the composition r includes menthol for a cooling effect. In a
particularly preferred embodiment, the composition includes the anti-irritant avena
sative kernel extract, the two vitamins nicotinamide and panthenol. and menthol.
[Annotation] tarranl
None set by tarranl
[Annotation] tarranl
MigrationNone set by tarranl
[Annotation] tarranl
Unmarked set by tarranl
[Annotation] tarranl
None set by tarranl
ation] tarranl
MigrationNone set by tarranl
[Annotation] tarranl
Unmarked set by tarranl
The composition of the present invention optionally further includes one or more
emulsifiers, emollients, ners, humectants. preservatives, body rs, pearlizing
agents, bulking agents, pH adjusters, feel modifiers, colouring agents and/or fragrances.
The composition of the invention can be a cream, lotion or gel.
In one , the cOmposition of the invention comprises:
a. disodium Iauriminodipropionate tocopheryl phosphate in an amount
equivalent to 1 to 5 percent (wlw) of a 40% active composition;
b. in combination with one or more of hamemalis virginiana water 0.5 to 10
percent (wlw);
c. nicotinamide 0.5 to 5 percent (wlw);
d. avena sativa kernel extract in an amount equivalent to 0.5 to 5 percent
(wlw) of a 100 ppm solution; and
e. menthol 0.01 to 0.1 percent (wlw).
Where the disodium inodipropionate tocopheryl ate in the above
composition is in a form comprising 40% (wlw) active ingredient, that form is 1, 2, 3, 4 or
percent (wlw) of the composition. More preferably, the disodium Iauriminodipropionate
tecopheryl phosphate in the above composition is in a form comprising 40% active
ingredient and that form is 3 percent (wlw) of the composition. Where the disodium
Iauriminodipropionate tocopheryl phosphate is not in a form comprising 40% active, the
active is preferably 1.2% (wlw) of the above composition.
The. avena sativa _kemel extract may be a 100 ppm solution. When in a 100 ppm
on it is preferred that solution is 0.5 to 5 percent (wlw) of the composition and most
preferred that the on is 1 percent (wlw) of the composition. Where the avena sativa
‘ kernel extract is in r form it is red that the active inthe extract is in an
amount lent to the amounts stated above.
In one embodiment, the disOdium Iauriminodipropionate tocopheryl phosphate is in
embocombifin with both the avena sativa kernel extract and the menthol. In an alternativent, the disodium, Iauriminodipropionate tocopheryl ate is in
combination with both the avena sativa kernel extract and the nicotinamide. In an
[Annotation] tarranl
None set by tarranl
[Annotation] tarranl
MigrationNone set by tarranl
[Annotation] tarranl
Unmarked set by tarranl
[Annotation] tarranl
None set by tarranl
[Annotation] tarranl
MigrationNone set by l
[Annotation] l
Unmarked set by tarranl
alternative embodiment, the disodium inodipropionate tocopheryl phosphate is in
combination with both the avena sativa kernel extract and the hamemalis virginiana
water. In a preferred embodiment, the disodium lauriminodipropionate tocopheryl
phosphate is in combination with the avena sativa kernel extract, the menthol and the
hamemalis virginiana water.
. In a preferred embodiment, the hamemalis virginiana water is in combination with all of
the four ients listed in the paragraph directly above. In this embodiment, the -
proportions are desirably:
disodium lauriminodipropionate tocopheryl ates 3.00 percent (w/w)
in the form of a 40% active composition;
'hamemalis virginiana water 3 t (w/w);
avena sativa kernel extract in a 100 ppm on 1 percent (w/w);
nicotinamide 1 percent (w/w); and
menthol 0.03 percent (WM).
'15 Alternatively. the proportions are desirably:
um Iauriminodipropidnate tocopheryl phosphates 1.2 percent (wlw);
hamemalis virginiana water 3 percent (w/w);
avena sativa kernel extract in an amount equivalent to 1 percent (w/w) of a
100 ppm solution;
‘20 nicotinamide 1 percent (w/w); and
menthol 0.031 percent (w/w).
In a prfired embodiment, the'composition consists essentially of:
a. um lauriminodipropionate tocopheryl phosphates ‘1 .2 percent (w/w);
[Annotation] tarranl
None set by tarranl
[Annotation] tarranl
ionNone set by tarranl
[Annotation] tarranl
Unmarked set by tarranl
[Annotation] l
None set by tarranl
ation] tarranl
MigrationNone set by tarranl
[Annotation] tarranl
Unmarked set by tarranl
b. hamemalis virginiana water 3 percent (w/w);
c. avena sativa kernel extract in an amount equivalent to 1 percent (w/w) of a
100 ppm solution;
d. nicotinamide 1 percent (w/w);
e. menthol 0.03 percent (w/w);
'f. one or more humectants, emollients, ners, emulsifiers,
preservatives, surfactants, pH adjusters, pearling, colouring or sent
; and
g. waterq.s..
1o In a further, aspect, the t invention provides the use of a physiologically effective
amount of a composition comprising disodium lauriminodipropionate tocopheryl
phOSphates in the preparation of a ment for increasing collagen in the skin of a
subject. It is preferred, that the medicament is also for the topical treatment or
prevention of thedevelopment or recurrence of erythema.
. In a further aspect. the present invention provides a composition comprising a
physiologically ‘ effective amount of a
, composition comprising disodium
lauriminodipropionate tocopheryl phosphates when used to increase collagen in the skin
.of’a subject. It is preferred, that the compositionxis also used in the topical treatment or
prevention of the development or recurrence of erythema.
In a further aspect, the present invention provides the use of a composition comprising
a' physiologically effective '
amount of a composition comprising disodium
lauriminodipropionate tocopheryl phosphates for increasing collagen in the skin of a
t. It is preferred, that the use is also for the l treatment or tion of the
development or recurrence of erythema.
The ified composition may be presented in a container with a pump dispenser.
The amount sed from the pump can vary but is about 200 milligrams with a fixed
% of active as described abOVe. One pump may supply a physiciogically effective
amourm about 2.5 mg disodium lauriminodipropionate eryl phosphates for
appli to the face. However, multiplepumps from the dispenser may also be
[Annotation] tarranl
None set by tarranl
[Annotation] tarranl
MigrationNone set by tarranl
[Annotation] tarranl
Unmarked set by tarranl
[Annotation] tarranl
None set by tarranl
[Annotation] tarranl
MigrationNone set by tarranl
[Annotation] tarranl
Unmarked set by tarranl
applied, for~ example, 2, 5 or 10 pumps to provide a physiologically effective dose to a
greater area of skin or to increase the amount of product used on the same area of skin.
.Without wishing to be bound by theory or mode of action, it is-considered that the
increase in the collagen in the skin in combination with the anti-inflammatory effect
caused by-to’pical administration of the compositions of the ion causes the
treatment or tion of the pment or recurrence of erythema.
Detailed description of the embodiments
It will be understood that various terms employed in the specification, examples and
claims have meanings that will be understood by one of ordinary skill in the art.
However, n terms are defined below.
As used , except where the context requires othewvise, the term "comprise" and
variations of the term, such as "comprising are» not
, comprises" and "comprised",
intended to exclude further additives, components, integers or steps.
The term “composition" as used hout the specification is understood‘to mean a
'15 Composition comprising a therapeutically effective amount‘of at least one therapeutic
agent and at least one pharrnaceutically acceptable r, excipient,'diluent. additive
or e consiStent with the intended form of topical administration and consistent with
I if
conventional pharmaceutical practices.
The term “disodium lauriminodipropionate eryl ates” as used throughout
the specification is understood to mean a blend of tocopherol phosphates with disodium
lauriminodipropionate having the International Nomenclature of Cosmetic Ingredients
(INCI) name “disodium lauriminodipropionate tocopheryl phosphates”.
The term “hamemalis iniana water’" as used throughout the specification is
understood to mean a witch hazel distillate, in particular, the witch hazel distillate having
the lntemational Nomenclature of Cosmetic Ingredients (INCI) name Hamemalis
Virginia (Witch Hazel) Water;
ation] tarranl
None set by tarranl
[Annotation] tarranl
MigrationNone set by tarranl
[Annotation] tarranl
Unmarked set by tarranl
[Annotation] tarranl
None set by l
[Annotation] tarranl
MigrationNone set by tarranl
[Annotation] tarranl
Unmarked set by tarranl
The term “therapeutic agent” or simply “agent” or “active" as used hout the
specification are understood to mean any substance that is intended for the diagnosis,
cure, mitigation, ent, tion or modification of a state in a biological system.
The term “physiologically effective” as used throughout the specification relates to the
amount or dose of an active agent or a ition thereof that will lead to the deSired
physiological effect, in particular, the ion or treatment of ma, prevention of
the development or recurrence of erythema or increase in en production in the
skin. A physiologically effective amount will vary according to factors such as the,
severity of the condition, age, gender, and skin type of a subject, and the y of the
'10 substance to elicit a desired response in the subject.
The term “Cetereth-ZO" as used throughout the specification s to a polyethylene
glycol ether of cetyl alcohol. Its synonyms include Ceteareth-20, Cetomacrogol 1000;
PEG-20 cetyl ether; PEG-20 hexadecyl ether; polyethylene glycol 1000 cetyl ether;
polyoxyethylene (20) cetyl ether.
The term “panthenol” as used throughout the specification es “dexpanthenol”.
The term “prevention” as used’throughout the specification means to inhibit, minimise,
defer or delay the onset of a condition.
The composition according to the present invention comprises a physiologically
ive amount of disodium Iauriminodipropionate tocopheryl ates. In *
embodiment, the compositions according to the present invention comprise disodium
lauriminodipropiOnate tocopheryl phosphates (40% active) in an amount of about 0.5 to
percent (MW). in' a preferred embodiment, the compositions according to the present
invention comprise um lauriminodipropionate tocopheryl phosphates (40% active)
in an amount of about 1 to 5 percent (w/w) or comprise disodium Iauriminodipropionate
tocopheryl phosphates active in an amount of about 0.5 to 2 percent (w/w). in a
particularly preferred embodiment, the composition comprises about 3 percent (w/w)
disodiqlauriminodiprOpionate tocopheryl phosphates (40% active) or 1.2 percent
(wlw) acrve disodium Iauriminodipropionate.tocopheryl phosphates .
[Annotation] tarranl
None set by tarranl
[Annotation] tarranl
MigrationNone set by tarranl
[Annotation] tarranl
ed set by tarranl
[Annotation] tarranl
None set by tarranl
[Annotation] tarranl
MigrationNone set by tarranl
[Annotation] tarranl
Unmarked set by tarranl
The composition of the invention can be a cream, lotion or gel. In a red
ment, the composition according to the present invention fUrther comprises at
least one emulsifier. Emulsifiers suitable for use in pharmaceutical compositions are
well known "to those of ordinary skill in the art and include, for example,
polyoxyethylene tive of sorbitan monolaurate such as polysorbate 20, fatty
alcohols such as cetearyl alcohol, ceteareth compounds, and emulsifying waxes. A
preferred emulsifier is ceteareth-20, which is commercially available from Croda under
the brand name Cetomacrogol 1000.
The amount of emulsifier added to the composition maybe y determined by one of
ordinary skill in the art With a minimum of experimentation, and 'will depend upon factors
known to those skilled in the art, such as the ties of the emulsifier and the desired
properties of the ceutical composition.
According to one ment of the present invention, the composition may include at
4 least one additional “skin active agent". Skin active agents may afford an improvement
715 in the appearance. tone or texture of the skin, and may include, but are not limited to,
sunscreens, anti-wrinkling or anti-aging agents, antioxidants, vitamins, depigmentating
'or skin lightening agents, rizing agents, emollients, metal ors, retinoids and
retinoid derivatives, agents intended'to reduce skin irritation. and alpha-hydroxy acids.
It will be recognised that the inclusion of skin active agents in the composition according
to the present invention will depend upon their physical, chemical and therapeutic
compatibility with the other components of the composition.
in one embodiment, the composition according to the present invention r
comprises an effective amount of at least one sunscreen. Examples of sunscreens
include, but are not d to, octyl methoxycinnamate, oxybenzone and butyl
'methoxydibenzoylmethane. Some such eens may- retain a more greasy feel but
the composition still provides a suitable delivery vehicle for a therapeutic, such as
mometasone furoate. In another embodiment the sunscreen is phenylbenzimidazol
sulfoninid or disodium phenyl imidazole ulfonate or similar.
[Annotation] tarranl
None set by tarranl
[Annotation] tarranl
MigrationNone set by l
[Annotation] tarranl
Unmarked set by tarranl
[Annotation] l
None set by tarranl
[Annotation] tarranl
MigrationNone set by tarranl
[Annotation] tarranl
Unmarked set by tarranl
In one ment, the composition according to the present invention may include at
least one additional rinkling or anti-aging agent. Examples of anti~wrinkling or anti-
aging agents include, but are not limited to, retinoids (for example, retinoic acid, retinol,
retinal, retinyl e, and retinyl palmitate), alpha hydroxy acids,\galactose' sugars (for
example, melibiose and lactose), lipoic acid and dihydrolipoic acid, lactoferrin, ascorbic
‘acid, and ascorbic acid derivatives '(for example ascorbyl palmitate and ascorbyl
polypeptide).
In another embodiment, the compositionaccording to'the present invention may include
at least one antioxidant or a natural extract that contains antioxidants. idants may
'10 be water or oil-soluble. Oil soluble antioxidants suitable for use in the composition of this
invention include, but areynot limited to, tocopherols and tocopherol derivatives (for
e, eryl acetate, alpha-tocopherol), tocotrienols and ubiquinone. Natural
extracts containing idants suitable for use in the composition of this invention,
include, but are not d to, extracts containing flavonoids, phenolic compounds,
,15 flavones, nes, isoflavonoids, mono-, di- and tri-terpenes, sterols and their
derivatives. Examples of such natural extracts include grape seed, green tea, pine bark
extracts and legume ts. idants may also ze skin irritation.
In another embodiment, the composition according to the present invention may include
at least one agent intended to inhibit or minimise potential skin irritation, such as an
emollient (e.g., liquid paraffin), a vitamin, an antioxidant (e.g., vitamin E) and a herbal
extract (e.g. ”aloe vera or avena sativa kernel extract). Avena sativa kernel extract is a
preferred [anti-irritant.
In another aspect according to the t invention, the composition comprises at least
one other ent intended to improve the appearance, stability or consumer appeal
of the composition; Such components include, but are not limited to: fragrances,
emollients, preservatives, vitamins and vitamin derivatives, antioxidants, colours,
humectants, plant extracts, surface active agents, and other ingredients to r
soothe and protect the skin.
ation] tarranl
None set by tarranl
[Annotation] tarranl
MigrationNone set by tarranl
[Annotation] tarranl
Unmarked set by tarranl
[Annotation] tarranl
None set by tarranl
[Annotation] tarranl
MigrationNone set by tarranl
[Annotation] tarranl
Unmarked set by tarranl
Again, it will be recognised that the inclusion of other components intended to improve
the appeal or stability of the composition according to the present invention will depend
upon their physical, chemical and therapeutic compatibility with the other components of
the composition. I
According to the present invention the term ‘stability’ refers to a composition that does
not present any significant macroscopic change of appearance or microsCopic change
of appearance-(e9, precipitation of an ingredient) over time.
In one ment, the composition according to the t invention comprises at
least one humectant. Examples of humectants include, but are not d to: glycerin,
glycerol, sodium PCA, panthenol/dexpanthenol, sorbitol, propylene glycol, 1,3—butylene
, polypropylene glycol, l, maititol, lactitoi, oat protein, oin, acetamine
MEA and hylauronicacid.
In another embodiment, the composition according to the present invention may
se at least one preservative. Examples of preservatives which may be used in
the composition of this invention include, but are not limited to, sodium salicylic acid,
chlorhexidine hydrochloride, phenoxyethanol, sodium te, sodium methyl
hydroxybenzoate, sodium propyl ybenzoate, methyl para-hydroxybenzoate (i.e.,
methyl paraben), ethyl para-hydroxybenzoate, propyl para~hydroxybenzoate (i.e., propyl
,paraben) and butyl para-hydroxybenzoate.
' in another embodiment, the composition according to the present invention may
comprise one or more ents. Parafflnum liquidum (liquid paraffin),
etrasiloxane and cylclopentasiloxane (Dow, Cylcomethicone 345) are suitable
emollients.
In another embodiment, the composition according to the present invention may
comprise one or more thickeners. Xantham gum and aristoflex AVC ium
acryloyldimethyI-taurateNP copolymer) are suitable thickeners.
_ln anoB embodiment, the composition according to the present invention may
- comprise one or more body builders such as cetearyl alcohol.
[Annotation] tarranl
None set by l
[Annotation] tarranl
MigrationNone set by tarranl
[Annotation] tarranl
Unmarked set by tarranl
[Annotation] tarranl
None set by tarranl
[Annotation] tarranl
ionNone set by tarranl
[Annotation] tarranl
Unmarked set by tarranl
In another embodiment, the composition according to the present invention may
comprise one .or more zing agents such as synthetic fluorophlogopite (and)
titanium dioxide (and) tin oxide (Timiron Synwhite 40).
in another embodiment, the composition according to the present invention may
comprise one or more bulk agents such as water.
The formulations of the present invention are manufactured in a conventional manner
by thoroughly mixing the ingredients at ambient or ed temperatures.
, Any ceutically acceptable acid may be employed to adjust the pH of the
pharmaceutical composition of the present invention to a pH suitable for a topical
1O composition. The identity of such acids are known to those of ordinary skill in the art,
and include, but are not limited to those described in the lntemational Cosmetic
Ingredient Dictionary and ok 12m Edition, 2008, Volume'3, pp 3221-3222,
Preferred acids are lactic acid, citric acid, hydrochloric acid and ic acid. A
particularly preferred acid is citricvacid.
.15 The examples that follow are intended to illustrate but in no way limit the present
invention;
Example 1 — ation of the composition
A composition suitable for use in the methods of the present ion can be prepared-
as follows:
[Annotation] tarranl
None set by tarranl
[Annotation] tarranl
MigrationNone set by tarranl
[Annotation] tarranl
ed set by tarranl
[Annotation] tarranl
None set by tarranl
[Annotation] tarranl
MigrationNone set by tarranl
[Annotation] tarranl
Unmarked set by tarranl
,—0.10
Sodium PCA
Cyclotetrasiloxane and
cyclopentasiloxane
Avena sativa kernel extract. 1.00
(100ppm solution) - .
iis virginiana water
Part F: Thickener
Ammonium acryloyldimethyl-
eNP copolymer
—3-50 ,
Synthetic fluorophlogopite (and)
titanium dioxide (and) tin oxide
Disodium Iauriminodipropionate 3;00
tocopheryl phosphate (40%
active) '
Methofi formulationi -
[Annotation] tarranl
None set by tarranl
[Annotation] tarranl
MigrationNone set by tarranl
[Annotation] tarranl
Unmarked set by tarranl
ation] tarranl
None set by tarranl
[Annotation] tarranl
MigrationNone set by tarranl
ation] tarranl
Unmarked set by tarranl
.1. Heat Part A water & citric acid to HBO-65°C
2. At 65 00 add Part-c and mix until dissolved
3. Add Part D with propeller mixing. Homogenise for 1 minute.
4. Cool batch to 50 °C with propeller mixing.-
. Combine Part A Glycerin and-Dexpanthenol and add to batch
6. Add Part E & B with propeller . Homogenise for ‘30 seconds
7. Combine Part F Glycerin, Xanthan gum and. Synthetic fluorophlogopite (and) titanium
- dioxide (and) tin oxide
8. Add ammonium'acryloyldimethyI—taurateNP copolymer then the rest of ‘Part F to the
‘10 Batch with propeller mixing
9. Cool batch to 45°C with propeller mixing.
. Add Part G with ler mixing
11. Homogenise for 2 minutes.
.15 Example 2 - increase of collagen l and III in the skin
Experimental protocol:
1. Human in ast (HFF) cells were seeded in a 96 well plate. 100p| of cells at
5X105 cells/ml was added per well in Dulbecco’s d eagle medium (DMEM) +
% fetal calf serum (FCS) + penicillin omycin (penstrep).
2. .The cells were incubated at 37°C in 5% C02 overnight
3. After 24 hrs the cells were transferred serum free media‘(SFM) for 6 hrs
4. The cell replated with SFM plus in 200;” of the composition formulated in Example 1.
SFM alone was used as a control.
. The cells were left at confluence for 60 hrs to allow collagen to build up
'6. Thulls were washed 3x with 100pl per well of phosphate buffered saline (PBS)
7. The cells were fixed and permeabilised in. ice cold MeOH (—20°C)
[Annotation] tarranl
None set by tarranl
[Annotation] tarranl
MigrationNone set by tarranl
[Annotation] tarranl
Unmarked set by tarranl
ation] tarranl
None set by tarranl
[Annotation] tarranl
MigrationNone set by tarranl
ation] tarranl
Unmarked set by tarranl
8. The fixed cells were transferred to the r for 15 minutes
9. The fixed cells were aspirated and air dried briefly then washed 3x with 100pl per well
of PBS and treated with Tween 20 (0.5%) in PBS for 10 minutes.
. The cells were blocked in 50pl per well PBS Tween + 3% normal goat serum (N68)
and incubated in '50pl per well. primary antibody in PBS + 3% NGS. For the collagen l
experiment the primary antibody was 1:200 Collagen l rabbit polyclonal antibody
(Rockland - Cat# 600—401-103.05). For thecollagen III experiment the primary antibody
was 1:200 Collagen Ill rabbit polyclonal antibody (Rockland - Cat# BOO—401405.05).
11. The cells were stored at room ature for 2 hours then washed 3x in 100pl per
Well PBSand incubated in mm per well Alexa conjugated secondary antibody in PBS.
The antibody used was 1:200 Alexa 488 goat anti-rabbit 'lgG (lnvitrogen - Cat# A
11008).
12. The cells were stored at room ature for 1 hour then washed 3x in 100pl per
well PBS and .100pl PBS was added to each well.
Analysis:
Analysis was ted on an Olympus IX81 fluorescence microscope, with Olympus
DP80 digital camera and CooILED light source. In both instances there was a 1.493
'20 second exposure and a 4x gain using the camera set to 0.6MP and with the light path
split between the ocular and camera. Images were captured and ed using
cellSens Dimension software us). Measurements are mean grey scale values of
14 bit images.
[Annotation] tarranl
None set by tarranl
[Annotation] tarranl
ionNone set by tarranl
[Annotation] tarranl
Unmarked set by tarranl
[Annotation] tarranl
None set by tarranl
[Annotation] tarranl
MigrationNone set by tarranl
[Annotation] tarranl
Unmarked set by tarranl
Table 1 - Collagen I
—w_l-Cellstreated with
exam . le 1
IEEIIIIIIIIIIIIIIIIIIIflfiflllllllliflZEIIIIIIIIIIIIIlifliilllllllllllllll
E_——_
IZEJBIIIIIIIIIIIIIIIIIIIII3§§IIIIIIlEBEEIIIIIIIIIIIIIIflliiallllllllllllllllll
IEEZIIIIIIIIIIIIIIIIIIlflilllllllIiIIEIIIIIIIIIIIIIIIEHEIIIIIIIIIIIIIIIII
IJZEIIIIIIIIIIIIIIIIIIIliiflllllllIiflalllllllllllllllliiflllllllllllllllll
IZEEIIIIIIIIIIIIIIIIIIIIZIIIIIIIIliEElIIIIIIIIIIIIIIIEEEIIIIIIIIIIIIIIIII
lIHIiIIIIIIIIIIIIIIIIIIIIIEIBIIIIIIIliilllllllllllllllllilBlIIIIIIIIIIIIIIII
008 _——
. lNfliflIIMiIIIIIIIIIIIIIIHIIHIBEEIIIIiZBilIIIIIIIIIIIIIIIBEZIIIIIIIIIIIIIIIII
————
[SEMIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIZIIIIIIIIIIIIIIIIIEIIIIIIIIIIIIIIIIII
—_——1
Mean OD percentage of- 100% ‘
SFM Mean OD ,
The results from Table‘ 1 are graphed in Figure 1. The graph shows a significant
difference in the collagen I levels in cells treated with serum free medium ed with
cells treated with the composition of example 1. The fluorescence for the cells treated
with serum free medium was about 6,300, while the fluorescence for the cells treated
' with the composition of example 1was about 7,300. This ents a 15% increase in
collagen l.
10A Table 2 — Collagen lll
Cells treated with
composition of
exam . le 1
[Annotation] tarranl
None set by tarranl
[Annotation] tarranl
ionNone set by tarranl
[Annotation] tarranl
Unmarked set by tarranl
ation] tarranl
None set by l
[Annotation] tarranl
MigrationNone set by tarranl
[Annotation] l
Unmarked set by tarranl
, 2.0
Cells treated with
composition of
exam - le 1
797' 8122 '
- 10265
739125 7 7499.0 10275.8
e ,
Mean loo — blank 6759.9 9536.6
Est-I— 163.8 '
P Value v control 1.47E-08 ’
Mean OD 100% 141% ”
percentage of SFM ‘
Mean OD ,
The results from Table 2 are graphed in Figure 2. The graph shows a significant
difference in the collagen Ill levels in cells treated with serum free medium compared
with cells treated with the composition of example 1’: The fluorescence for the cells
treated with serum free ] was about 6,800. while the fluorescence for the cells
treated with the composition of example 1 was about 9,500. This represents a 41%
increase in collagen lll.
' Example 3
— reduction in erythema
Experimental protocol:
1. The baseline assessment for each test participant was determined a day befOre
exposure to the Solar tor at time = -1.
2. A Solar Simulator was used to induce mild erythema on 7 designated areas of the
back of test subjects at time = 0.
l ‘
3. The composition of example 1 or a control of 1% hydrocortisone cream was topically
applied to the irradiated skin immediately after irradiation and again 4-5 hours later. The
{Composition or positive control was rubbed in Well upon each ation. There was
also a negative control involving irradiation and assessment without topical application.
4. Test subjects returned for assessment at 24 hours (i=1), 2 days (i=2), 4 days (t=3)
and 7 «fl (t=4).
[Annotation] tarranl
None set by tarranl
[Annotation] tarranl
MigrationNone set by tarranl
[Annotation] tarranl
Unmarked set by tarranl
ation] tarranl
None set by tarranl
[Annotation] tarranl
MigrationNone set by tarranl
[Annotation] tarranl
ed set by l
. ment involved visual assessment and scoring of the erythema. In addition,
colorometric measurements were taken using a Minolta Spectrophotometer Model CM,
2600 and the L*a*t)* colour space values recorded. The L Value measures skin
lightening, the a*b* values indicate change in tone against the background skin tone. _
Total colour change (AE) = \/(AL2 + Aa2 + Abz). Assessments at T=1 are compared with .
, =2, T=3 and T=4 to quantify the improvement in colour over time.
6. Visual assessment g was madeaccording to the Standard Scalar Ratings:
0 = no erythema present
1 = minimal faint (light pink), uniform or spotty erythema
2 = mild erythema, pink uniform erythema covering most of contact site
3 = moderate erythema, pink/red erythema visibly. uniform in entire contact area »
'4 = marked bright red erythema
= severe deep red ma
Results:
'15 Table 5 - AE
U-V only, negative
control
Positive control
Composition of
exam . le 1
Table 6 - magenta to blue shift (a* at the nt time point minus the initial a*
D value)
[Annotation] tarranl
None set by l
ation] tarranl
ionNone set by tarranl
[Annotation] tarranl
Unmarked set by l
[Annotation] tarranl
None set by tarranl
[Annotation] tarranl
MigrationNone set by tarranl
[Annotation] tarranl
Unmarked set by tarranl
_T=2 — T=1 T=3 — T=1 ‘
1:4 ._ 1:1
control
Positive control
I1 -
exam - lo 1
'Table 7 - Visual assessment scoring
reduction0
UV only, 3.8 1.6 76.30
. negafive
control '
‘-----ucontrol
Inn-nu-ofexam- le 1
ltwill be understood that the invention disclosed and defined in this specification
extends to all alternative combinations of two or more of the individual features
mentioned or evident from the text. All of these different combinations constitute various
alternative aspects of the invention.
Claims (24)
1. Use of a physiologically effective amount of a composition comprising disodium lauriminodipropionate tocopheryl phosphate, avena sativa kernel extract, nicotinamide, hamemalis virginiana water, and menthol in the preparation of a medicament formulated for the topical treatment, tion or tion of recurrence of ma caused by external irritation of the skin of a subject, wherein the al irritation of the skin is selected from over exposure to the sun and contact with an irritating substance.
2. The use of claim 1, n the irritating nce is a plant or a metal.
3. The use according to claim 1 or claim 2, wherein the use reduces the Standard Scalar Rating for the erythema by either (i) 77% or more; or (ii) 3.0 or more after 7 days.
4. The use according to any one of claims 1-3, wherein the use results in (i) a magenta to blue shift (a*) of -2.5 or a greater negative; and/or (ii) a ΔE of 3.5 or more by 48 hours after use as ed by a Minolta Spectrometer; or the method results in (i) a magenta to blue shift of -4 or a greater negative and/or (ii) a ΔE of 5 or more by 7 days after use as measured by a Minolta Spectrometer.
5. The use according to any one of claims 1-4, wherein the medicament is for the maintenance of skin health.
6. The use according to any one of claims 1-5, wherein the medicament also increases the collagen in the skin of the subject.
7. The use according to claim 6, wherein the increased collagen comprises increased production of collagen in fibroblasts in the skin. 1003244951
8. The use according to claim 6 or claim 7, wherein the use increases production of collagen III by about 10% or more and/or increases production of collagen I by about 5% or more.
9. The use according to claim 8, wherein the use increases production of collagen III by about 40% and/or increases production of collagen I by about 15%.
10. The use according to any one of claims 1-9, wherein the composition is a cream, lotion or gel.
11. The use ing to any one of claims 1-10, wherein the ition further es the vitamin panthenol or dexpanthenol.
12. The use according to any one of claims 1-11, n the composition is an emulsion.
13. The use of any one of claims 1-12, wherein the composition further includes one or more emulsifiers, ents, thickeners, ants, preservatives, body builders, bulking agents, pH adjusters, and/or feel modifiers.
14. The use according to claim 13, wherein the composition further comprises at least one emulsifier selected from the group ting of polyoxyethylene derivative of sorbitan monolaurate such as polysorbate 20, fatty alcohols such as cetearyl alcohol, ceteareth compounds, and emulsifying waxes.
15. The use according to claim 14, wherein the emulsifier is ceteareth-20.
16. The use according to any one of claims 1-15, wherein the disodium lauriminodipropionate tocopheryl phosphate is in a form comprising 40% active ingredient and that form is 3 % (w/w) of the composition.
17. The use according to any one of claims 1-16, wherein the disodium lauriminodipropionate tocopheryl ate active is 1.2% (w/w) of the composition. 1003244951
18. The use according to any one of claims 1-17, wherein the ition comprises: a. hamemalis virginiana water 0.5 to 10 % (w/w); b. disodium lauriminodipropionate tocopheryl phosphate in an amount equivalent to 1 to 5 % (w/w) of a 40% active composition; c. nicotinamide 0.5 to 5 % (w/w); d. avena sativa kernel extract in an amount equivalent to 0.5 to 5 % (w/w) of a 100 ppm solution; and e. l 0.01 to 0.1 % (w/w).
19. The use according to claim 18, wherein the composition comprises: a. disodium lauriminodipropionate tocopheryl phosphates 1.2 % (w/w); b. hamemalis iana water 3 % (w/w); c. avena sativa kernel extract in an amount equivalent to 1 % (w/w) of a 100 ppm solution; d. nicotinamide 1 % (w/w); and e. menthol 0.03 % (w/w).
20. The use according to claim 19, wherein the composition consists ially a. disodium lauriminodipropionate tocopheryl phosphates in an amount equivalent to 1.2 percent (w/w); b. hamemalis virginiana water 3 percent (w/w); c. avena sativa kernel extract in an amount equivalent to 1 percent (w/w) of a 100 ppm solution; d. namide 1 percent (w/w); e. menthol 0.03 percent (w/w); f. one or more humectants, emollients, thickeners, emulsifiers, preservatives; surfactants, pH ers and pearling, colouring or scent agents; and g. water q.s. 1003244951
21. The use according to any one of claims 1-20, wherein the physiologically effective amount is about 2.5mg disodium lauriminodipropionate tocopheryl phosphate applied to the face.
22. The use according to any one of claims 1-21, wherein the composition is in a container with a pump dispenser.
23. The use according to claim 22, wherein the pump dispenses about 200 milligrams.
24. The use according to claim 22 or claim 23, n one pump supplies about 2.5 mg disodium lauriminodipropionate eryl phosphates. 1003244951 [Annotation] tarranl None set by tarranl [Annotation] l MigrationNone set by tarranl [Annotation] tarranl Unmarked set by tarranl [Annotation] tarranl None set by tarranl ation] tarranl MigrationNone set by tarranl [Annotation] tarranl Unmarked set by tarranl
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ751394A NZ751394B2 (en) | 2014-03-12 | Compositions that assist skin healing and/or maintain skin health |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/AU2014/000241 WO2015135016A1 (en) | 2014-03-12 | 2014-03-12 | Compositions that assist skin healing and/or maintain skin health |
NZ751394A NZ751394B2 (en) | 2014-03-12 | Compositions that assist skin healing and/or maintain skin health | |
NZ721641A NZ721641A (en) | 2014-03-12 | 2014-03-12 | Compositions that assist skin healing and/or maintain skin health |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ751394A NZ751394A (en) | 2020-11-27 |
NZ751394B2 true NZ751394B2 (en) | 2021-03-02 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Felsten et al. | Vitiligo: A comprehensive overview: Part II: Treatment options and approach to treatment | |
Sahu et al. | Study of oral tranexamic acid, topical tranexamic acid, and modified Kligman's regimen in treatment of melasma | |
US8008345B2 (en) | Dermal therapy using phosphate derivatives of electron transfer agents | |
Ibrahim et al. | Evaluation of the efficacy and safety of combinations of hydroquinone, glycolic acid, and hyaluronic acid in the treatment of melasma | |
US20070270358A1 (en) | Cosmetic and/or Pharmaceutical Composition for the Treatment of the Rosacea | |
AU2002317053A1 (en) | Dermal therapy using phosphate derivatives of electron transfer agents | |
Woolery‐Lloyd et al. | Sodium L‐ascorbyl‐2‐phosphate 5% lotion for the treatment of acne vulgaris: a randomized, double‐blind, controlled trial | |
JP2009507016A (en) | Novel skin care composition | |
US8647682B2 (en) | Composition and method for treating keratosis pilaris | |
Lueangarun et al. | Clinical efficacy of 0.5% topical mangosteen extract in nanoparticle loaded gel in treatment of mild‐to‐moderate acne vulgaris: A 12‐week, split‐face, double‐blinded, randomized, controlled trial | |
McDaniel et al. | Evaluation of the antioxidant capacity and protective effects of a comprehensive topical antioxidant containing water-soluble, enzymatic, and lipid-soluble antioxidants | |
WO2018075810A1 (en) | Dermatological compositions for providing nutrients to skin and methods thereof | |
Salim et al. | Melasma | |
AU2020204232B2 (en) | Compositions that assist skin healing and/or maintain skin health | |
Khan et al. | Synergistic effects of ascorbyl palmitate and sodium ascorbyl phosphate loaded in multiple emulsions on facial skin melanin and erythema content | |
CZ31798A3 (en) | Cosmetic way of treating and prevention signs of skin ageing | |
NZ751394B2 (en) | Compositions that assist skin healing and/or maintain skin health | |
US10786441B2 (en) | Skin barrier repair and maintenance composition | |
US20170216350A1 (en) | Compositions of aluminum fluoride and methods of use thereof for the treatment and prevention of actinic keratosis and sun-induced damages | |
US12036310B2 (en) | Skin rejuvenating composition | |
Manriquez et al. | SECTION 4: Disorders of pigmentation | |
Grimes et al. | Evaluation of an advanced antioxidant and double‐conjugated retinoid/AHA cream in participants with FST IV–V | |
WO2024102219A1 (en) | Compositions including caffeic acid phenethyl ester | |
Trüeb et al. | Exemplary case studies of successful treatments | |
Gowda | A Comparitive Study of Clinical Efficacy of 35% Glycolic Acid and 20% Salicylic Acid Peels in Melasma at Navodaya Medical College Hospital & Research Centre, Raichur |